Comprehensive Stock Comparison
Compare Syra Health Corp. Class A Common Stock (SYRA) vs Solventum Corporation (SOLV) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | SYRA | 44.7% revenue growth vs SOLV's 0.9% |
| Quality / Margins | SOLV | 18.7% net margin vs SYRA's -16.9% |
| Stability / Safety | SYRA | Beta 0.78 vs SOLV's 0.97, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | SOLV | -7.0% vs SYRA's -75.3% |
| Efficiency (ROA) | SOLV | 10.9% ROA vs SYRA's -38.8%, ROIC 16.9% vs -294.7% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Syra Health is a healthcare services company that provides health education, population health management, behavioral health, workforce solutions, and digital health services. It generates revenue through service contracts with government agencies, health networks, and pharmaceutical manufacturers — primarily from its health education and population health management segments. The company's competitive advantage lies in its integrated service portfolio addressing multiple healthcare system pain points, including its Syrenity telehealth platform for mental health services.
Solventum is a healthcare company that develops, manufactures, and commercializes medical solutions across four main segments. It generates revenue primarily from medical surgical supplies (~40% of sales), dental products (~25%), health information systems software (~20%), and purification/filtration technologies (~15%). The company benefits from its established brand recognition and comprehensive product portfolio—spanning from wound care to dental orthodontics—which creates switching costs for healthcare providers.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
SOLV leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). SYRA leads in 1 (Valuation Metrics). 1 tied.
Financial Metrics (TTM)
SOLV is the larger business by revenue, generating $8.3B annually — 1110.2x SYRA's $7M. SOLV is the more profitable business, keeping 18.7% of every revenue dollar as net income compared to SYRA's -16.9%. On growth, SOLV holds the edge at -3.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SYRASyra Health Corp.… | SOLVSolventum Corpora… |
|---|---|---|
| RevenueTrailing 12 months | $7M | $8.3B |
| EBITDAEarnings before interest/tax | -$1M | $2.9B |
| Net IncomeAfter-tax profit | -$1M | $1.6B |
| Free Cash FlowCash after capex | -$231,031 | -$9M |
| Gross MarginGross profit ÷ Revenue | +31.4% | +53.5% |
| Operating MarginEBIT ÷ Revenue | -16.9% | +26.2% |
| Net MarginNet income ÷ Revenue | -16.9% | +18.7% |
| FCF MarginFCF ÷ Revenue | -3.1% | -0.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -25.1% | -3.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +67.1% | +105.6% |
Valuation Metrics
| Metric | SYRASyra Health Corp.… | SOLVSolventum Corpora… |
|---|---|---|
| Market CapShares × price | $60,000 | $12.9B |
| Enterprise ValueMkt cap + debt − cash | -$2M | $17.0B |
| Trailing P/EPrice ÷ TTM EPS | -0.19x | 8.36x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 11.54x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 7.81x |
| Price / SalesMarket cap ÷ Revenue | 0.01x | 1.55x |
| Price / BookPrice ÷ Book value/share | 0.25x | 2.58x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
SOLV delivers a 30.8% return on equity — every $100 of shareholder capital generates $31 in annual profit, vs $-57 for SYRA. SYRA carries lower financial leverage with a 0.16x debt-to-equity ratio, signaling a more conservative balance sheet compared to SOLV's 1.00x. On the Piotroski fundamental quality scale (0–9), SOLV scores 6/9 vs SYRA's 3/9, reflecting solid financial health.
| Metric | SYRASyra Health Corp.… | SOLVSolventum Corpora… |
|---|---|---|
| ROE (TTM)Return on equity | -57.3% | +30.8% |
| ROA (TTM)Return on assets | -38.8% | +10.9% |
| ROICReturn on invested capital | -2.9% | +16.9% |
| ROCEReturn on capital employed | -106.4% | +19.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 |
| Debt / EquityFinancial leverage | 0.16x | 1.00x |
| Net DebtTotal debt minus cash | -$2M | $4.2B |
| Cash & Equiv.Liquid assets | $2M | $878M |
| Total DebtShort + long-term debt | $452,077 | $5.0B |
| Interest CoverageEBIT ÷ Interest expense | -99.37x | 5.62x |
Total Returns (with DRIP)
A $10,000 investment in SOLV five years ago would be worth $9,275 today (with dividends reinvested), compared to $333 for SYRA. Over the past 12 months, SOLV leads with a -7.0% total return vs SYRA's -75.3%. The 3-year compound annual growth rate (CAGR) favors SOLV at -2.5% vs SYRA's -67.8% — a key indicator of consistent wealth creation.
| Metric | SYRASyra Health Corp.… | SOLVSolventum Corpora… |
|---|---|---|
| YTD ReturnYear-to-date | +14.9% | -6.1% |
| 1-Year ReturnPast 12 months | -75.3% | -7.0% |
| 3-Year ReturnCumulative with dividends | -96.7% | -7.2% |
| 5-Year ReturnCumulative with dividends | -96.7% | -7.3% |
| 10-Year ReturnCumulative with dividends | -96.7% | -7.2% |
| CAGR (3Y)Annualised 3-year return | -67.8% | -2.5% |
Risk & Volatility
SYRA is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than SOLV's 0.97 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SOLV currently trades 84.1% from its 52-week high vs SYRA's 24.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SYRASyra Health Corp.… | SOLVSolventum Corpora… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.78x | 0.97x |
| 52-Week HighHighest price in past year | $0.41 | $88.20 |
| 52-Week LowLowest price in past year | $0.03 | $60.70 |
| % of 52W HighCurrent price vs 52-week peak | +24.4% | +84.1% |
| RSI (14)Momentum oscillator 0–100 | 51.5 | 50.9 |
| Avg Volume (50D)Average daily shares traded | 12K | 788K |
Analyst Outlook
| Metric | SYRASyra Health Corp.… | SOLVSolventum Corpora… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $95.80 |
| # AnalystsCovering analysts | — | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Apr 24 | Feb 26 | Change |
|---|---|---|---|
| Syra Health Corp. C… (SYRA) | 100 | 5.59 | -94.4% |
| Solventum Corporati… (SOLV) | 86.37 | 96.14 | +11.3% |
Solventum Corporati… (SOLV) returned -7% over 5 years vs Syra Health Corp. C… (SYRA)'s -97%.
Chart 2Revenue Growth — 10 Years
| Stock | 2020 | 2025 | Change |
|---|---|---|---|
| Syra Health Corp. C… (SYRA) | $0.00 | $8M | — |
| Solventum Corporati… (SOLV) | $8.2B | $8.3B | +1.9% |
Chart 3Net Margin Trend — 10 Years
| Stock | 2021 | 2025 | Change |
|---|---|---|---|
| Syra Health Corp. C… (SYRA) | -0.2% | -47.1% | -20147.6% |
| Solventum Corporati… (SOLV) | 17.9% | 18.7% | +4.6% |
Solventum Corporation's net margin went from 18% (2021) to 19% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2020 | 2025 | Change |
|---|---|---|---|
| Syra Health Corp. C… (SYRA) | -0 | -0.52 | -74185.7% |
| Solventum Corporati… (SOLV) | 8.47 | 8.88 | +4.8% |
Chart 5Free Cash Flow — 5 Years
Syra Health Corp. Class A Common Stock generated $-3M FCF in 2024 (-3015% vs 2021). Solventum Corporation generated $-10M FCF in 2025 (-101% vs 2021).
SYRA vs SOLV: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is SYRA or SOLV a better buy right now?
Solventum Corporation (SOLV) offers the better valuation at 8.4x trailing P/E (11.5x forward), making it the more compelling value choice. Analysts rate Solventum Corporation (SOLV) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SYRA or SOLV?
Over the past 5 years, Solventum Corporation (SOLV) delivered a total return of -7.3%, compared to -96.7% for Syra Health Corp. Class A Common Stock (SYRA). A $10,000 investment in SOLV five years ago would be worth approximately $9K today (assuming dividends reinvested). Over 10 years, the gap is even starker: SOLV returned -7.2% versus SYRA's -96.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SYRA or SOLV?
By beta (market sensitivity over 5 years), Syra Health Corp. Class A Common Stock (SYRA) is the lower-risk stock at 0.78β versus Solventum Corporation's 0.97β — meaning SOLV is approximately 24% more volatile than SYRA relative to the S&P 500. On balance sheet safety, Syra Health Corp. Class A Common Stock (SYRA) carries a lower debt/equity ratio of 16% versus 100% for Solventum Corporation — giving it more financial flexibility in a downturn.
04Which has better profit margins — SYRA or SOLV?
Solventum Corporation (SOLV) is the more profitable company, earning 18.7% net margin versus -47.1% for Syra Health Corp. Class A Common Stock — meaning it keeps 18.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SOLV leads at 26.2% versus -47.2% for SYRA. At the gross margin level — before operating expenses — SOLV leads at 53.5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — SYRA or SOLV?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is SYRA or SOLV better for a retirement portfolio?
For long-horizon retirement investors, Syra Health Corp. Class A Common Stock (SYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.78)). Both have compounded well over 10 years (SYRA: -96.7%, SOLV: -7.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between SYRA and SOLV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: SYRA is a small-cap quality compounder stock; SOLV is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.